As a part of her on going recovery, she still gets screeningS regularly and encourages her daughter to do the same. This ...

As the nights draw in Bryony Fernandez is preparing for the next phase of helping her fiancé, Jon Ward, to access the ...

The antibody-drug conjugate will be reviewed for the potential treatment of previously treated, unresectable or metastatic ...

Trial results suggested the antibody-drug conjugate may be a treatment option for patients with HER2 metastatic breast cancer ...

AstraZeneca and Daiichi Sankyo's supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) has ...

Jennifer McNeill claimed she visited her GP and A&E several times, but was told it was muscular. A mum who struggled to lift ...

Black women are more likely to be affected by breast cancer compared to their counterparts. A new FDA ruling can improve ...

MU Health’s Ellis Fischel Cancer Center in Columbia is a cancer treatment and research hub. Dr. Nicole Nelson said innovative ...

Trastuzumab deruxtecan is a HER2-directed antibody and topoisomerase inhibitor conjugate currently marketed under the brand name Enhertu (fam-trastuzumab deruxtecan-nxki) for the treatment of breast ...

With this year's Breast Cancer Awareness Month now underway, we are sharing eight facts and updates about breast cancer that ...

The FDA expects to issue a decision in the first quarter of 2025, and if the agency grants approval, it will expand the biomarker-eligible population for the drug.

The FDA grants priority review to AZN's sBLA for Enhertu to treat HER2-low or HER2-ultralow metastatic breast cancer. A ...